RxDoctor Payments Data

Adam Schneider, MD

Neurology · Jericho, NYNPI 1124137948

Payments from drug & device makers

$4,947in general payments, 2019–2025

Across 256 payments — averaging $19.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$525
  • Neurocrine Biosciences, Inc.$224
  • Lilly USA, LLC$204
  • Biohaven Pharmaceuticals, Inc.$183
  • Otsuka America Pharmaceutical, Inc.$154
  • plus $1K from 24 others

What the payments were for

  • Speaking & faculty fees$170%
  • Food & beverage$4,930100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,947 in reported general payments places this provider in the 60th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$196,643
Medicare patients
384
Services billed
1,509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate11$53,846
Nurtec OdtRimegepant Sulfate16$15,431
BotoxOnabotulinumtoxina11$12,942
VimpatLacosamide12$12,549
DilantinPhenytoin Sodium Extended12$8,228
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone13$4,075
Pregabalin91$3,849
Donepezil Hcl163$2,495
Gabapentin83$1,226
Carbidopa-LevodopaCarbidopa/Levodopa71$998
Memantine Hcl58$733
Phenobarbital28$418
Topiramate23$171
Escitalopram Oxalate13$167
Pramipexole DihydrochloridePramipexole Di-Hcl15$81

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Dilantin$53$23,65928 claims
AbbVieBotox$2,311$12,94211 claims
UCB, Inc.Vimpat$525$12,54912 claims
Upsher-smith Laboratories LLCTopiramate$111$17123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,623 neurology providers in New York.

Other neurology in Jericho

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →